The development of small molecules for their use in modern day medicine has existed since the 19th century and has developed into a 1 trillion dollar pharmaceutical industry. Small molecules represents the vast majority of drugs dispensed today and exciting advances in their use and ability to treat and cure disease will ensure they will thrive well into the next century.
Despite their ubiquity, small molecule drug development is a highly specialised industry, and each successful blockbuster that makes the journey to market has been beset on all sides by risk and failure. Such a journey requires a great understanding from contract manufacturing organisations (CMOs) to be active and dynamic to respond to pharmaceutical customers during the process.
In this webinar, an overview of the development and lifecycle of a small molecule drug is presented. Attention is then turned to the typical needs and requirements for an API manufacturer at each stage of the lifecycle. We then present a case study of how a CMO, such as Cambrex, has the expertise to support customers at all stages from early development to commercial launch.